Tromethamine salt of bimatoprost acid in crystalline form 1, methods for preparation, and methods for use thereof

Patent metadata

Field	Value
Publication number	US-10273206-B2
Application number	US-201414318402-A
Country	US
Kind code	B2
Filing date	Jun 27, 2014
Priority date	Jun 27, 2014
Publication date	Apr 30, 2019
Grant date	Apr 30, 2019

Abstract

The present invention provides tromethamine salt of (Z)-7-[3,5-Dihydroxy-2-((E)-3-hydroxy-5-phenyl-pent-1-enyl)-cyclopentyl]-hept-5-enoic acid in crystalline Form 1 and amorphous form. This compound is may also be referred to as “tromethamine salt of bimatoprost acid.” The invention crystalline form is useful for solid ocular implant or topical formulations, utilized in the treatment of various ocular conditions, such as, for example, ocular hypertension.

First claim

What is claimed is:

1. A method for localized fat reduction comprising administering to a subject in need thereof a therapeutically effective amount of a crystalline form of the tromethamine salt of bimatoprost acid in an pharmaceutically acceptable carrier, wherein the crystalline form of the tromethamine salt of bimatoprost acid has an X-ray powder diffraction pattern with peaks at 6.80°, 10.18°, 13.35°, 16.10°, 17.30°, 17.99°, 19.05°, 19.35°, 19.95°, 20.40°, 21.11°, 22.85°, 23.25°, 24.46°, 25.22° and 33.73° of 2-theta (Cu, K-alpha1 radiation with wavelength 1.5406 Å).

2. A method for promotion of hair growth comprising administering to a subject in need thereof a therapeutically effective amount of a crystalline form of the tromethamine salt of bimatoprost acid an pharmaceutically acceptable carrier, wherein the crystalline form of the tromethamine salt of bimatoprost acid has an X-ray powder diffraction pattern with peaks at 6.80°, 10.18°, 13.35°, 16.10°, 17.30°, 17.99°, 19.05°, 19.35°, 19.95°, 20.40°, 21.11°, 22.85°, 23.25°, 24.46°, 25.22° and 33.73° of 2-theta (Cu, K-alpha1 radiation with wavelength 1.5406 Å).

Assignees

• Allergan Inc

Inventors

• Karami Thomas K
• Smith Scott W
• Dubas-Fisher Fiona
• St Clair Brown Adrian

Classifications

• C07C215/10

  with one amino group and at least two hydroxy groups bound to the carbon skeleton · CPC title

• C07C405/00 Primary

  Compounds containing a five-membered ring having two side-chains in ortho position to each other, and having oxygen atoms directly attached to the ring in ortho position to one of the side-chains, one side-chain containing, not directly attached to the ring, a carbon atom having three bonds to hetero atoms with at the most one bond to halogen, and the other side-chain having oxygen atoms attached in gamma-position to the ring, e.g. prostaglandins {; Analogues or derivatives thereof} · CPC title

• C07C2601/10

  the ring being unsaturated · CPC title

• C07B2200/13

  Crystalline forms, e.g. polymorphs · CPC title